Spyre Therapeutics, Inc. (FRA:3920)
Germany · Delayed Price · Currency is EUR | Market Cap | 7.19B +681.8% |
| Revenue (ttm) | n/a |
| Net Income | -131.48M |
| EPS | -1.76 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 23 |
| Open | 75.50 |
| Previous Close | 70.50 |
| Day's Range | 75.50 - 75.50 |
| 52-Week Range | 16.00 - 92.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 6, 2026 |
About Spyre Therapeutics
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the α4β7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn’s disease); and SPY002 and SPY072 – anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also develo... [Read more]
News
Spyre Therapeutics initiated with a Buy at UBS
UBS initiated coverage of Spyre Therapeutics (SYRE) with a Buy rating and $120 price target The firm views Spyre as the best way to play inflammatory bowel disease combination therapies.
Spyre Therapeutics falls -12.8%
Spyre Therapeutics (SYRE) is down -12.8%, or -$11.90 to $80.81.
Spyre Therapeutics falls -8.4%
Spyre Therapeutics (SYRE) is down -8.4%, or -$7.80 to $84.92.
Spyre Therapeutics 4.12M share Spot Secondary priced at $85.00
Jefferies, TD Cowen, Leerink and Stifel are acting as joint book running managers for the offering. The deal size was increased to $350M from $250M and priced below last closing…
Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation the...
Spyre Therapeutics $250M Spot Secondary; re-offered at $85.00 per share
Jefferies, TD Cowen, Leerink Partners and Stifel are acting as the joint book-running managers for the proposed offering.
Spyre Therapeutics announces common stock offering, no amount given
Spyre Therapeutics (SYRE) announced that it has commenced an underwritten public offering of its common stock. Jefferies, TD Cowen, Leerink Partners and Stifel are acting as the joint book-running man...
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation the...
Spyre Therapeutics Announces Grants of Inducement Awards
WALTHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation the...
Spyre Therapeutics price target raised to $130 from $121 at Jones
Jones analyst Debanjana Chatterjee raised the firm’s price target on Spyre Therapeutics (SYRE) to $130 from $121 and keeps a Buy rating on the shares. The firm cites greater conviction…
Spyre Therapeutics initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of Spyre Therapeutics (SYRE) with an Overweight rating and $110 price target The company has six clinical-stage assets in development for inflammatory bowel disease, the an...
Spyre Therapeutics rises 6.8%
Spyre Therapeutics (SYRE) is up 6.8%, or $5.72 to $90.44.
Spyre Therapeutics Transcript: Stifel 2026 Virtual Immunology and Inflammation Forum
The forum highlighted a strategy centered on best-in-class, long-acting antibody combinations for autoimmune diseases, with IBD as the lead indication. SKYLINE study results next year will guide advancement in both UC and Crohn's, while promising data in HS and rheumatology support further expansion.
Spyre Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference
Focused on advancing optimized biologic combinations for autoimmune diseases, the company is running a global, near-phase III scale trial in IBD, with monotherapy and combination arms. Long-acting antibodies show efficacy and dosing advantages, and upcoming readouts in IBD, HS, and other indications will guide phase III priorities. Strong financials support multiple late-stage programs.
Spyre Therapeutics Transcript: Citigroup’s Biopharma Back to School Summit 2026
The company is advancing best-in-class antibody therapies for autoimmune diseases, with a focus on IBD and expansion into rheumatic and dermatologic indications. Strong recent data, a robust financial position, and a differentiated co-formulation strategy support multiple upcoming readouts and potential market leadership.
Spyre Therapeutics announces 12-week induction data from Part A of SKYLINE trial
Spyre Therapeutics (SYRE) announced positive 12-week induction data from Part A of the Phase 2 SKYLINE trial of SPY003, an anti-IL-23 being investigated for the treatment of moderately-to-severely act...
Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations
SPY003 met its primary endpoint with a statistically significant reduction of 10.0 points (p
Spyre Therapeutics to Participate in Upcoming September Investor Conferences
WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the st...
Spyre Therapeutics falls -13.2%
Spyre Therapeutics (SYRE) is down -13.2%, or -$14.16 to $93.20.
Spyre Therapeutics falls -11.6%
Spyre Therapeutics (SYRE) is down -11.6%, or -$12.47 to $94.89.
Spyre Therapeutics price target lowered to $123 from $130 at Wedbush
Wedbush lowered the firm’s price target on Spyre Therapeutics (SYRE) to $123 from $130 and keeps an Outperform rating on the shares. The firm notes the company reported topline Phase…
Spyre Therapeutics price target lowered to $121 from $132 at BTIG
BTIG lowered the firm’s price target on Spyre Therapeutics (SYRE) to $121 from $132 and keeps a Buy rating on the shares. The firm cites the company’s findings on SPY072,…
Spyre Therapeutics price target lowered to $127 from $135 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Spyre Therapeutics (SYRE) to $127 from $135 and keeps a Buy rating on the shares following the topline results from the rheumatoid…
Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072
Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpo...
Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Announced positive topline induction data for SPY001 and SPY002 from Part A of the Phase 2 SKYLINE trial (“SKYLINE”), demonstrating best-in-class efficacy potential and a safety profile consistent wit...